Follow
Carlo Gambacorti Passerini
Carlo Gambacorti Passerini
Professor
Verified email at unimib.it - Homepage
Title
Cited by
Cited by
Year
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
H Kantarjian, C Sawyers, A Hochhaus, F Guilhot, C Schiffer, ...
New England Journal of Medicine 346 (9), 645-652, 2002
26772002
Clinical and biological implications of driver mutations in myelodysplastic syndromes
E Papaemmanuil, M Gerstung, L Malcovati, S Tauro, G Gundem, ...
Blood, The Journal of the American Society of Hematology 122 (22), 3616-3627, 2013
19702013
Pan-cancer analysis of whole genomes
Nature 578 (7793), 82-93, 2020
1641*2020
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study: Presented in part at …
CL Sawyers, A Hochhaus, E Feldman, JM Goldman, CB Miller, ...
Blood, The Journal of the American Society of Hematology 99 (10), 3530-3539, 2002
15252002
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
M Talpaz, RT Silver, BJ Druker, JM Goldman, C Gambacorti-Passerini, ...
Blood, The Journal of the American Society of Hematology 99 (6), 1928-1937, 2002
14602002
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
E Papaemmanuil, M Cazzola, J Boultwood, L Malcovati, P Vyas, D Bowen, ...
New England Journal of Medicine 365 (15), 1384-1395, 2011
14162011
A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias
JE Cortes, DW Kim, J Pinilla-Ibarz, P Le Coutre, R Paquette, C Chuah, ...
New England Journal of Medicine 369 (19), 1783-1796, 2013
12182013
Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells
V Zuco, R Supino, SC Righetti, L Cleris, E Marchesi, ...
Cancer letters 175 (1), 17-25, 2002
7132002
Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
P le Coutre, E Tassi, M Varella-Garcia, R Barni, L Mologni, G Cabrita, ...
Blood, The Journal of the American Society of Hematology 95 (5), 1758-1766, 2000
7002000
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial
JE Cortes, DW Kim, HM Kantarjian, TH Brümmendorf, I Dyagil, ...
Journal of Clinical Oncology 30 (28), 3486, 2012
5522012
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
F Passamonti, C Cattaneo, L Arcaini, R Bruna, M Cavo, F Merli, ...
The Lancet Haematology 7 (10), e737-e745, 2020
5382020
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
JE Cortes, HM Kantarjian, TH Brümmendorf, DW Kim, AG Turkina, ...
Blood, The Journal of the American Society of Hematology 118 (17), 4567-4576, 2011
5252011
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib
C Gambacorti-Passerini, L Antolini, FX Mahon, F Guilhot, M Deininger, ...
Journal of the National Cancer Institute 103 (7), 553-561, 2011
5142011
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
S Redaelli, R Piazza, R Rostagno, V Magistroni, P Perini, M Marega, ...
Journal of clinical oncology: official journal of the American Society of …, 2008
5142008
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
CB Gambacorti-Passerini, RH Gunby, R Piazza, A Galietta, R Rostagno, ...
The lancet oncology 4 (2), 75-85, 2003
5072003
Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial
JE Cortes, DW Kim, J Pinilla-Ibarz, PD le Coutre, R Paquette, C Chuah, ...
Blood, The Journal of the American Society of Hematology 132 (4), 393-404, 2018
5022018
In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor
P Le Coutre, L Mologni, L Cleris, E Marchesi, E Buchdunger, R Giardini, ...
Journal of the National Cancer Institute 91 (2), 163-168, 1999
4901999
Role of α1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI571
C Gambacorti-Passerini, R Barni, P le Coutre, M Zucchetti, G Cabrita, ...
Journal of the National Cancer Institute 92 (20), 1641-1650, 2000
4882000
Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial
JE Cortes, C Gambacorti-Passerini, MW Deininger, MJ Mauro, C Chuah, ...
Journal of Clinical Oncology 36 (3), 231, 2018
4662018
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells
M Puttini, AML Coluccia, F Boschelli, L Cleris, E Marchesi, ...
Cancer research 66 (23), 11314-11322, 2006
4662006
The system can't perform the operation now. Try again later.
Articles 1–20